- Home
- INSM vs ABEV Comparison
INSM vs ABEV Comparison
Compare INSM & ABEV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INSM
- ABEV
- Stock Information
- Founded
- INSM 1988
- ABEV 1885
- Country
- INSM United States
- ABEV Brazil
- Employees
- INSM N/A
- ABEV N/A
- Industry
- INSM Biotechnology: Pharmaceutical Preparations
- ABEV Beverages (Production/Distribution)
- Sector
- INSM Health Care
- ABEV Consumer Staples
- Exchange
- INSM Nasdaq
- ABEV Nasdaq
- Market Cap
- INSM 29.0B
- ABEV 33.8B
- IPO Year
- INSM 2000
- ABEV N/A
- Fundamental
- Price
- INSM $189.60
- ABEV $2.31
- Analyst Decision
- INSM Strong Buy
- ABEV Hold
- Analyst Count
- INSM 19
- ABEV 4
- Target Price
- INSM $171.12
- ABEV $2.35
- AVG Volume (30 Days)
- INSM 2.1M
- ABEV 51.2M
- Earning Date
- INSM 10-30-2025
- ABEV 10-30-2025
- Dividend Yield
- INSM N/A
- ABEV 7.46%
- EPS Growth
- INSM N/A
- ABEV N/A
- EPS
- INSM N/A
- ABEV 0.15
- Revenue
- INSM $447,022,000.00
- ABEV $16,593,832,111.00
- Revenue This Year
- INSM $32.08
- ABEV $5.86
- Revenue Next Year
- INSM $125.86
- ABEV $4.97
- P/E Ratio
- INSM N/A
- ABEV $15.30
- Revenue Growth
- INSM 30.34
- ABEV 7.32
- 52 Week Low
- INSM $60.40
- ABEV $1.76
- 52 Week High
- INSM $197.08
- ABEV $2.64
- Technical
- Relative Strength Index (RSI)
- INSM 76.69
- ABEV 61.27
- Support Level
- INSM $154.79
- ABEV $2.18
- Resistance Level
- INSM $168.22
- ABEV $2.25
- Average True Range (ATR)
- INSM 6.44
- ABEV 0.05
- MACD
- INSM 1.81
- ABEV 0.01
- Stochastic Oscillator
- INSM 82.31
- ABEV 80.77
About INSM Insmed Incorporated
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.
About ABEV Ambev S.A.
Ambev is the largest brewer in Latin America and the Caribbean and is Anheuser-Busch InBev's subsidiary in the region. It produces, distributes, and sells beer and PepsiCo products in Brazil and other Latin American countries and owns Argentina's largest brewer, Quinsa. Ambev was formed in 1999 through the merger of Brazil's two largest beverage companies, Brahma and Antarctica. In 2004, Ambev combined with Canadian brewer Labatt, giving AB InBev a controlling interest of 62%.